학술논문
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Document Type
Article
Author
Rugo, Hope S ; Lerebours, Florence; Ciruelos, Eva; Drullinsky, Pamela; Ruiz-Borrego, Manuel; Neven, Patrick; Park, Yeon Hee; Prat, Aleix; Bachelot, Thomas; Juric, Dejan; Turner, Nicholas; Sophos, Nickolas; Zarate, Juan Pablo; Arce, Christina; Shen, Yu-Ming; Turner, Stuart; Kanakamedala, Hemanth; Hsu, Wei-Chun; Chia, Stephen
Source
In The Lancet Oncology April 2021 22(4):489-498
Subject
Language
ISSN
1470-2045